QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
ASX:AVR

Anteris Technologies (AVR) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)
Free AVR Stock Alerts
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
6.45%
Price Target
N/A
Stock Analysis
Stock Analysis
AVR stock logo

About Anteris Technologies Stock (ASX:AVR)

Anteris Technologies Ltd, a structural heart company, designs, develops, and commercializes medical devices. The company manufactures and sells ADAPT, a regenerative tissue product. Its lead product is the DurAVRTM, a transcatheter heart valve for the treatment of aortic stenosis. The company was formerly known as Admedus Limited and changed its name to Anteris Technologies Ltd in May 2020. Anteris Technologies Ltd was incorporated in 1999 and is based in Toowong, Australia.

AVR Stock News Headlines

April 12, 2024 | finance.yahoo.com
Those who invested in Anteris Technologies (ASX:AVR) five years ago are up 292%
March 6, 2024 | msn.com
ASX 200 recoups early losses as major banks push higher, tech stocks pull back
April 19, 2024 | Behind the Markets (Ad)
The #1 Opportunity of the decade?
It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.
March 6, 2024 | wsj.com
Anteris Technologies Ltd.
March 2, 2024 | afr.com
Anteris Technologies Ltd
February 29, 2024 | finance.yahoo.com
Anteris Technologies Full Year 2023 Earnings: Misses Expectations
February 8, 2024 | finance.yahoo.com
Anteris Technologies Ltd's (ASX:AVR) largest shareholders are retail investors with 50% ownership, institutions own 29%
January 20, 2024 | finance.yahoo.com
Anteris Technologies Ltd (AVR.XA)
April 19, 2024 | Behind the Markets (Ad)
The #1 Opportunity of the decade?
It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.
December 19, 2023 | msn.com
FDA submission looms as Artrya’s AI platform aims to capture the huge cardio diseases market
November 29, 2023 | proactiveinvestors.com.au
FDA approval for BiVACOR's artificial heart study paves further paths for heart tech innovation
November 21, 2023 | morningstar.com
Anteris Technologies Ltd AVR
November 21, 2023 | proactiveinvestors.com.au
FIVE at FIVE AU: Mining lifts ASX; RBA minutes suggest further rate hikes
November 20, 2023 | proactiveinvestors.com.au
Anteris Technologies fields "excellent" 30-day haemodynamic...Anteris Technologies fields "excellent" 30-day haemodynamic...
November 20, 2023 | proactiveinvestors.com
Anteris Technologies fields "excellent" 30-day haemodynamic...
October 30, 2023 | proactiveinvestors.com
Anteris talks market superiority of its biomimetic TAVR valve
October 17, 2023 | proactiveinvestors.com
Anteris Technologies completes DurAVRTM Early Feasibility Study enrolment
October 12, 2023 | proactiveinvestors.com.au
FIVE at FIVE AU: ASX slips and US markets stumble on higher-than-expected CPI
September 12, 2023 | au.investing.com
Anteris Technologies to present latest clinical data for DurAVR™
September 12, 2023 | finance.yahoo.com
Anteris Announces Participation at the Cantor Healthcare Conference on Sept 26th 2023
August 14, 2023 | businesswire.com
DurAVR™ THV Demonstrates Exceptional Results in Second Valve-in-Valve Case
August 9, 2023 | finance.yahoo.com
Anteris Technologies Commences US Early Feasibility Study
August 9, 2023 | finance.yahoo.com
Anteris Technologies Commences American Depository Receipt Program
August 1, 2023 | proactiveinvestors.com.au
Anteris welcomes successful DurAVR valve-in-valve procedure
July 31, 2023 | finance.yahoo.com
Anteris Technologies Announces First Successful Implantation of DurAVR™ THV in a Valve-in-Valve Procedure
July 30, 2023 | au.investing.com
Anteris Technologies’ DurAVR heart valve used in life-saving valve-in-valve procedure
June 14, 2023 | finance.yahoo.com
Anteris Technologies says latest first-in-human DurAVR™ results are next-level
See More Headlines
Receive AVR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anteris Technologies and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
Current Symbol
ASX:AVR
CUSIP
N/A
CIK
N/A
Web
www.anteristech.com
Phone
61 1300 550 310
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
A($4.31)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-67,330,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-329.00%
Return on Assets
-127.62%

Debt

Debt-to-Equity Ratio
8.14
Current Ratio
2.60
Quick Ratio
4.07

Sales & Book Value

Annual Sales
$4.11 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
A$1.61 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
18,100,000
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.75
The 10 Best AI Stocks to Own in 2024 Cover
The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Wayne G. Paterson (Age 57)
    CEO, MD & Executive Director
    Comp: $1.93M
  • Mr. Matthew McDonnell
    Chief Financial Officer
  • Mr. David St. Denis
    Chief Operating Officer
  • Dejan Toracki
    Corporate Development Director
  • Dr. Chris Meduri M.D.
    M.P.H., Chief Medical Officer & Member of Medical Advisory Board
  • Mr. Stephen Denaro
    Independent Non-Executive Director & Company Secretary

Key Competitors

View All Competitors

Insiders


This page (ASX:AVR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
The #1 Crypto for 2024
InvestorPlace
Your Money is Not Safe
American Alternative